Project Grant P01CA288368
Award Date
8/16/24
Completion Date
7/31/29
Dollars Obligated
$3.8M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand the fundamental biological mechanisms driving acquired cross-resistance in small cell lung cancer (SCLC). The $642,429 award to the University of Texas Southwestern Medical Center, effective January 1, 2025 through December 31, 2029, aims to investigate how extrachromosomal MYC amplifications contribute to broad chemotherapy resistance in SCLC patient-derived...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $230,010 to the University of Chicago to conduct research aimed at unraveling the mechanisms driving metastasis in small cell lung cancer (SCLC). The research strategy integrates human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing to investigate the cellular and molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $216,972 to Temple University to conduct research aimed at understanding and targeting vulnerabilities related to the G1/S cell cycle transition and replication stress in small cell lung cancer (SCLC). The key products and services to be delivered include: Determining the mechanistic underpinnings of increased replication stress in SCLC, including the role of low LMNA (a nuclear...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine supports research aimed at understanding and disrupting the adeno-to-squamous transition, a mechanism by which non-small cell lung cancer can adapt and become resistant to targeted therapies like KRAS inhibitors. The $703,410 award, effective January 16, 2025 through December 31, 2029, will fund a comprehensive research program to identify specific...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $701,538 to the Icahn School of Medicine at Mount Sinai to investigate the lineage evolution and epigenomic signatures of a distinct subtype of small cell lung cancer (SCLC) characterized by the lineage factor NKX2-1. The research aims to: 1) Determine how cell-of-origin and NKX2-1 impact the evolution and maintenance of this SCLC epigenomic subtype, 2) Elucidate the...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
The National Cancer Institute (NCI) awarded a $1,592,358 Project Grant (CFDA 93.396 Cancer Biology Research) to The Leland Stanford Junior University (Stanford University) to conduct research on modulating cysteine metabolism to induce cell death in small cell lung cancer (SCLC). The project aims to determine how cysteine deprivation triggers cell state-specific lethal mechanisms in SCLC cells, focusing on the role of the GCN2/ATF4 amino acid sensing pathway, polyunsaturated phospholipid...
The National Cancer Institute (NCI) awarded a $548,915 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Fred Hutchinson Cancer Center in Seattle, WA. The grant will fund research to elucidate the biological roles of a stress-activated protein kinase (SAPK) pathway as a tumor suppressor axis in small cell lung cancer (SCLC). The researchers will leverage cellular models, genetically engineered mouse models, and human tumor datasets to define the impact...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $191,675 to The University of Texas Southwestern Medical Center to investigate the role of the Jumonji KDM4A enzyme in small cell lung cancer (SCLC). The primary goals are to determine if Jumonji inhibition can block SCLC growth, including in chemotherapy-resistant disease, by reprogramming key neuroendocrine transcription factor gene programs. The research will utilize novel...